Tissue Regenix Group (LSE:TRX) ROCE % : -1.60% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tissue Regenix Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -1.60%.

Tissue Regenix Group ROCE % Historical Data

The historical data trend for Tissue Regenix Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group ROCE % Chart

Tissue Regenix Group Annual Data

Trend

Jan14

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-23.62

-30.41

-10.20

-5.37

-1.34

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-11.00	-6.33	-4.26	-1.09	-1.60

Tissue Regenix Group ROCE % Calculation

Tissue Regenix Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.419	/	( ( (37.798 - 5.455)	+	(34.162 - 3.741) )	/ 2 )
	=	-0.419	/	( (32.343	+	30.421)	/ 2 )
	=	-0.419	/	31.382
	=	-1.34 %

Tissue Regenix Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-0.494	/	( ( (35.591 - 4.388)	+	(34.162 - 3.741) )	/ 2 )
	=	-0.494	/	( ( 31.203	+	30.421 )	/ 2 )
	=	-0.494	/	30.812
	=	-1.60 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Tissue Regenix Group (LSE:TRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tissue Regenix Group ROCE % Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LSW:Germany

Address

Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website

https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.